Skip to main content
SpringerLink
Log in

Counterfeit Botulinum Medical Products and Risk of Bioterrorism

  • Living reference work entry
  • First Online:
Toxinology

Abstract

Botulinum toxin has established a strong, worldwide position for the treatment of a wide range of clinical and aesthetic conditions. The products have brought considerable benefits to patients, from children with cerebral palsy to older patients with stroke-related conditions. Aesthetic use alone is probably over 10 million treatments per year and rising rapidly. The latest licensed applications in pain treatment and urology are amongst a range of new applications also under study. With this overall rise in clinical use, an increase in the availability of counterfeit and fake products has occurred. These products are readily available from Internet sources and may be purchased by doctors or patients. Their quality is, however, of considerable concern, in particular their content of excess amounts of active botulinum toxin in some cases and their lack of assurance of sterility for an injectable product. The potential for the sources of such products to become providers for bioterrorist activities is therefore of key importance. Can botulinum toxin from medical sources become a terrorist weapon? The background to this situation is discussed in detail, and the potential for such medical product use for bioterrorism acts is considered, using case studies.

The author is also Senior Program Leader and Scientific Expert, Neurotoxins for Galderma Aesthetic and Corrective. The opinions and comments expressed in this chapter are those of the author and Toxin Science Limited only.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abrams A, Kegeles G, Hottle GA. The purification of toxin from Clostridium botulinum type A. J Biol Chem. 1946;164:63–79.

    CAS  PubMed  Google Scholar 

  • Alberts B. Modeling attacks on the food supply. Proc Natl Acad Sci U S A. 2005;102(28):9737–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Al-Saleem FH, Ancharski DM, Joshi SG, Elias M, Singh A, Nasser Z, Simpson LL. Analysis of the mechanisms that underlie absorption of botulinum toxin by the inhalation route. Infect Immun. 2012;80(12):4133–42.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Announcement by Islamic Republic of Iran Broadcasting (2012). Video recording at: http://www.dailymotion.com/video/xo6i3a_iran-unveils-six-new-life-saving-drugs_news. Accessed 14 Jan 2012.

  • Balali-Mood M, Moshiri M, Etemad L. Medical aspects of bio-terrorism. Toxicon. 2013;69:131–42.

    Article  CAS  PubMed  Google Scholar 

  • Berry MG, Stanek JJ. Botulinum neurotoxin A: a review. J Plast Reconstr Aesthet Surg. 2012;65(10):1283–91.

    Article  CAS  PubMed  Google Scholar 

  • Bossi P, Tegnell A, Baka A, van Loock F, Hendriks J, Werner A, Maidhof H, Gouvras G, Public Health Directorate European Commission Luxembourg Task Force on Biological and Chemical Agent Threats. Bichat guidelines for the clinical management of botulism and bioterrorism-related botulism. Euro Surveill. 2004;9(12):E13–4.

    PubMed  Google Scholar 

  • Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weisman RS, Bernstein J, Marcus SM, Kumar S, Malecki J, Sobel J, Braden CR. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296(20):2476–9.

    Article  CAS  PubMed  Google Scholar 

  • Coleman K, Zilinskas RA. Fake botox, real threat. Sci Am. 2010;302(6):84–9.

    Article  PubMed  Google Scholar 

  • Coleman KD, Zalinskas RA. The security threat from producers of counterfeit botulinum toxin. Phase 1: scoping out the problem. James Martin Center for Nonproliferation Studies. USA: Monterey Institute of International Studies; 2011. p. 53

    Google Scholar 

  • Crawford JA, Kronenberg J, Beare J, Starner A, Scorpio A, Blight S. Impact of molecular weight and serotype on botulinum neurotoxin oral toxicity and stability in simulated gastrointestinal tract conditions. Botulinum J. 2012;2(2):109–18.

    Article  Google Scholar 

  • D’Aniello S, Somorjai I, Garcia-Fernàndez J, Topo E, D’Aniello A. d-Aspartic acid is a novel endogenous neurotransmitter. FASEB J. 2011;25(3):1014–27.

    Article  PubMed  Google Scholar 

  • Feily A, Fallahi H, Zandian D, Kalantar H. A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use. J Cosmet Dermatol. 2011;10(1):58–67.

    Article  PubMed  Google Scholar 

  • Graham R, Schwarze H, Boughton IB. The relation of contaminated rations to the presence of C. Botulinum in the milk of lactating animals. Am J Public Health (NY). 1922;12(8):659–65.

    Article  CAS  Google Scholar 

  • Hunt T, Clarke K. Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test. J Am Acad Dermatol. 2008;58(3):517–8.

    Article  PubMed  Google Scholar 

  • Khardori N. Bioterrorism preparedness, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA.; 2006.

    Book  Google Scholar 

  • Knutsson R. A tracing tool portfolio to detect Bacillus anthracis, Clostridium botulinum and Noroviruses: bioterrorism is a food safety and security issue. Int J Food Microbiol. 2011;145 Suppl 1:S121–2.

    Article  PubMed  Google Scholar 

  • Lamanna C, McElroy OE, Eklund HW. The purification and crystallization of Clostridium botulinum type A toxin. Science. 1946;103(2681):613–4.

    Article  CAS  Google Scholar 

  • Li ZJ, Park SB, Sohn KC, Lee Y, Seo YJ, Kim CD, Kim YS, Lee JH, Im M. Regulation of lipid production by acetylcholine signalling in human sebaceous glands. J Dermatol Sci. 2013;72:116–22.

    Article  CAS  PubMed  Google Scholar 

  • Liang BA, Mackey TK, Lovett K. Emerging dangers from direct botulinum access and use. J Homel Secur Emerg Manage. 2012;9(1).

    Google Scholar 

  • Marcus SM. Reflections on the care of a patient severely poisoned by “rogue” botulinum toxin and rendered paralysed for a protracted hospital stay. Botulinum J. 2009;1(3):318–39.

    Article  Google Scholar 

  • Morse SA. Bioterrorism. Croatia: InTech.; 2012. p. 192.

    Book  Google Scholar 

  • Oh SH, Lee Y, Seo YJ, Lee JH, Yang JD, Chung HY, Cho BC. The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg. 2012;38(10):1689–94.

    Article  CAS  PubMed  Google Scholar 

  • Pacini S, Gulisano M, Punzi T, Ruggiero M. Transdermal delivery of Clostridium botulinum toxin type A by pulsed current iontophoresis. J Am Acad Dermatol. 2007;57(6):1097–9.

    Article  PubMed  Google Scholar 

  • Park JB, Simpson LL. Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun. 2003;71(3):1147–54.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013;4(2):10.

    Article  PubMed Central  PubMed  Google Scholar 

  • Pickett A. Bootleg toxins. Body Language. 2010;38:14–5.

    Google Scholar 

  • Pickett A. Fake botulinum toxin products in clinical use. Presented at WCBP: Symposium on the Interface of Regulatory and Analytical Sciences for Biological Products; 2011; Washington DC.

    Google Scholar 

  • Pickett A. Toxins and the fake market, 2013. Presented at IMCAS ASIA; 2013; Singapore. p. 2222.

    Google Scholar 

  • Pickett A, Mewies M. Counterfeit botulinum toxins: a serious risk to patient safety. Presented at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Baveno (TOXINS 2008); 2008; Baveno.

    Google Scholar 

  • Pickett A, Mewies M. Counterfeit botulinum toxins – a serious risk to patient safety. Presented at IMCAS; 2009a; Paris.

    Google Scholar 

  • Pickett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol. 2009b;61(1):149–50.

    Google Scholar 

  • Pilch RF, Zilinskas RA. Encyclopedia of bioterrorism defense. Hoboken: Wiley-Liss; 2011.

    Google Scholar 

  • Rao S, Starr RL, Morris MG, Lin WJ. Variations in expression and release of botulinum neurotoxin in Clostridium botulinum type A strains. Foodborne Pathog Dis. 2007;4(2):201–7.

    Article  CAS  PubMed  Google Scholar 

  • Rasooly R, Do PM. Clostridium botulinum Neurotoxin type B Is heat-stable in milk and not inactivated by pasteurization. J Agric Food Chem. 2010;58(23):12557–61.

    Article  CAS  PubMed  Google Scholar 

  • Risks and benefits of dual-use research. Nature. 2005;435(7044):855.

    Google Scholar 

  • Sanford DC, Barnewall RE, Vassar ML, Niemuth N, Metcalfe K, House RV, Henderson I, Shearer JD. Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1. Clin Vaccine Immunol. 2010;17(9):1293–304.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev. 1992;56(1):80–99.

    CAS  PubMed Central  PubMed  Google Scholar 

  • Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3(4):333–5.

    Article  CAS  PubMed  Google Scholar 

  • Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology. 2006;67(10):1855–6.

    Article  CAS  PubMed  Google Scholar 

  • Stancombe PR, Masuyer G, Birch-Machin I, Beard M, Foster KA, Chaddock JA, Acharya KR. Engineering botulinum neurotoxin domains for activation by toxin light chain. FEBS J. 2012;279(3):515–23.

    Article  CAS  PubMed  Google Scholar 

  • Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A. 2005;102(28):9984–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Weingart OG, Schreiber T, Mascher C, Pauly D, Dorner MB, Berger TF, Egger C, Gessler F, Loessner MJ, Avondet MA, Dorner BG. The case of botulinum toxin in milk: experimental data. Appl Environ Microbiol. 2010;76(10):3293–300.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Xiao Z, Qu G. Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules. 2012;17(2):2169–77.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Toxin Science Limited, Wrexham, UK

    Andy Pickett

  2. Botulinum Research Center, UMASS Dartmouth, Dartmouth, MA, USA

    Andy Pickett

Authors
  1. Andy Pickett
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andy Pickett .

Editor information

Editors and Affiliations

  1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

    P. Gopalakrishnakone

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this entry

Cite this entry

Pickett, A. (2014). Counterfeit Botulinum Medical Products and Risk of Bioterrorism. In: Gopalakrishnakone, P. (eds) Toxinology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6645-7_28-1

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-6645-7_28-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Online ISBN: 978-94-007-6645-7

  • eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Search

Navigation